[go: up one dir, main page]

MX2019001121A - Nuevas formulaciones y composiciones de cannabis en comprimidos y metodos para su elaboracion. - Google Patents

Nuevas formulaciones y composiciones de cannabis en comprimidos y metodos para su elaboracion.

Info

Publication number
MX2019001121A
MX2019001121A MX2019001121A MX2019001121A MX2019001121A MX 2019001121 A MX2019001121 A MX 2019001121A MX 2019001121 A MX2019001121 A MX 2019001121A MX 2019001121 A MX2019001121 A MX 2019001121A MX 2019001121 A MX2019001121 A MX 2019001121A
Authority
MX
Mexico
Prior art keywords
compositions
methods
tablets
cannabis
preparation
Prior art date
Application number
MX2019001121A
Other languages
English (en)
Other versions
MX382609B (es
Inventor
Levy Kurt
Original Assignee
Canopy Growth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61017335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019001121(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Canopy Growth Corp filed Critical Canopy Growth Corp
Publication of MX2019001121A publication Critical patent/MX2019001121A/es
Publication of MX382609B publication Critical patent/MX382609B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones que comprenden un aceite que tiene por lo menos un cannabinoide y por lo menos un polvo sólido y métodos para elaborar y usando las mismas. Las composiciones son apropiadas para hacer comprimidos que contienen cannabinoides prensando una composición de la presente invención con uno o más agentes de formulación, como por ejemplo aglutinantes, cargas, agentes para aumentar el volumen, excipientes, etc.
MX2019001121A 2016-07-25 2017-07-25 Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración. MX382609B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662366517P 2016-07-25 2016-07-25
PCT/US2017/043808 WO2018022669A1 (en) 2016-07-25 2017-07-25 New cannabis tablet formulations and compositions and methods of making the same

Publications (2)

Publication Number Publication Date
MX2019001121A true MX2019001121A (es) 2019-10-21
MX382609B MX382609B (es) 2025-03-13

Family

ID=61017335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001121A MX382609B (es) 2016-07-25 2017-07-25 Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración.

Country Status (12)

Country Link
US (3) US20190183850A1 (es)
EP (1) EP3487482A4 (es)
CN (1) CN109789095A (es)
AU (1) AU2017302559A1 (es)
BR (1) BR112019001528A8 (es)
CA (1) CA3031533A1 (es)
CL (1) CL2019000198A1 (es)
CO (1) CO2019000787A2 (es)
IL (1) IL264386B2 (es)
MX (1) MX382609B (es)
PE (1) PE20200478A1 (es)
WO (1) WO2018022669A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3755309A1 (en) * 2018-02-23 2020-12-30 Columbia Care LLC Hard-pressed scored splittable marijuana tablets
WO2019211772A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Obtaining extracts in a solid form
US20210393573A1 (en) * 2018-10-30 2021-12-23 Kelsie Biotech, Llc Tablets, formulations and methods for low melting point active ingredients
US20220023220A1 (en) * 2019-01-10 2022-01-27 Columbia Care Llc Rapidly disintegrating oral tablet
CA3040547C (en) 2019-04-17 2021-12-07 Medcan Pharma A/S Cannabinoid lozenge formulation
US11633351B2 (en) 2019-12-13 2023-04-25 Nordiccan A/S Fast disintegrating cannabinoid tablets
US10925853B2 (en) 2019-04-17 2021-02-23 Nordiccan A/S Oral cannabinoid tablet
AU2021206021A1 (en) * 2020-01-08 2022-06-02 Société des Produits Nestlé S.A. Oral solid cannabinoid oil composition for treating gastrointestinal disorders
MX2023013814A (es) * 2021-05-21 2024-05-27 Swm Luxembourg Sarl Proceso para incorporar aditivos en sustratos productores de aerosol y productos elaborados a partir de los mismos.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7908791A (en) * 1990-05-08 1991-11-27 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
US6077543A (en) * 1996-12-31 2000-06-20 Inhale Therapeutic Systems Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
JP4467883B2 (ja) * 2001-02-14 2010-05-26 ジーダブリュー・ファーマ・リミテッド 医薬製剤
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
ATE516796T1 (de) * 2006-09-15 2011-08-15 Echo Pharmaceuticals Bv Granulat mit einem pharmazeutischen wirkstoff und einem emulgator und herstellungsverfahren dafür
CN101810593B (zh) * 2010-05-10 2012-07-18 谢恬 一种榄香烯缓释片
US11077086B2 (en) * 2014-07-21 2021-08-03 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
CA2968929A1 (en) 2014-11-26 2016-06-02 One World Cannabis Ltd Synergistic use of cannabis for treating multiple myeloma
US10172786B2 (en) 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids

Also Published As

Publication number Publication date
US20210100771A1 (en) 2021-04-08
US20220323403A1 (en) 2022-10-13
IL264386A (en) 2019-02-28
IL264386B2 (en) 2023-08-01
AU2017302559A1 (en) 2019-02-07
WO2018022669A1 (en) 2018-02-01
CO2019000787A2 (es) 2019-04-30
US20190183850A1 (en) 2019-06-20
CA3031533A1 (en) 2018-02-01
IL264386B1 (en) 2023-04-01
BR112019001528A8 (pt) 2019-07-09
BR112019001528A2 (pt) 2019-06-18
EP3487482A4 (en) 2020-03-04
CN109789095A (zh) 2019-05-21
EP3487482A1 (en) 2019-05-29
CL2019000198A1 (es) 2019-05-31
MX382609B (es) 2025-03-13
PE20200478A1 (es) 2020-03-03

Similar Documents

Publication Publication Date Title
MX2019001121A (es) Nuevas formulaciones y composiciones de cannabis en comprimidos y metodos para su elaboracion.
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
MX2016010216A (es) Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos.
MX2016014555A (es) Composiciones novedosas, usos y metodos para hacerlas.
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
CO2018005753A2 (es) Composición hemostática
MX378687B (es) Formulacion de vitamina soluble en grasa.
BR112018002983A2 (pt) composição compreendendo uma lactama e um álcool
ECSP22012650A (es) Composiciones que comprenden tigolaner para el control de parásitos
MX2020001969A (es) Composiciones de reduccion del mal olor.
BR112016024096A2 (pt) novo bacteriófago e composição compreendendo o mesmo
MX2018001512A (es) Composiciones antimicrobianas que comprenden mupirocina y neomicina.
MX385910B (es) Composiciones de fragancia que comprenden ciclohexanoato de etilo.
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
BR112017018618A2 (pt) odorizante de osmanthus
CO2017004809A2 (es) Composiciones de triptamidas
AR101736A1 (es) Composiciones que contienen zinc, con aceites esenciales